The University Of Texas Health Science Center At San Antonio

Hispanic and Latino people make up 20% of the U.S. population but only 6% of physicians. A panel discussion highlighted the need for more Latino physicians, the importance of trust and language concordance in clinical trials, and the diverse backgrounds within the Latino community. Efforts to educate and support Latino clinicians and researchers are crucial for health equity.

UT Health San Antonio's Dr. Marzieh Salehi refutes the calorie-in-calorie-out myth for obesity, emphasizing the complexity of gut-organ communication in metabolism. Her translational research aims to understand this communication better, particularly in populations like those with spinal cord injuries, through a clinical trial on semaglutide's effects, funded by NIH.

Fellowship recipients must be full-time researchers on sabbatical, managing Tk 470 million and Tk 330 million projects. Keshab Chandra Das took study leave in March 2020, working on PhD and projects despite COVID-19 disruptions, receiving Tk 40,000/month. NIB faces complaints on recruitment, vehicle rentals, and seniority list irregularities. Prof. Shahedur Rahman critiques the Institute of Biotechnology's underperformance and long-term leadership issues.

Verona Pharma presents Phase 3 ENHANCE studies on Ohtuvayre (ensifentrine), a first-in-class dual PDE3/PDE4 inhibitor for COPD, at CHEST 2024, showing efficacy in lung function, symptoms, and quality of life across various patient subgroups.

A $3 million NIH-funded study led by Marzieh Salehi, MD, MS, at UT Health San Antonio investigates the antidiabetic and anti-obesity effects of semaglutide in people with spinal cord injury, aiming to impact treatment guidelines and understand underlying diabetes mechanisms in this population.